The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and health systems.
Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By combining data from diagnostic tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans with their patients.
PMC's Strategic Plan for Advancing Personalized Medicine in 2023 arrives at a moment when the contention upon which PMC was founded — that a paradigm shift toward personalized medicine will not occur just because new tests and treatments have become available — is more evident than ever.
PMC research shows, for example, that due to the influence of testing and treatment difficulties occurring at each of seven steps in the precision oncology pathway, personalized medicine benefitted only 36 percent of a cohort of 38,068 patients diagnosed in 2019 with advanced non-small cell lung cancer, a disease that presents major opportunities for a genetically personalized approach. With more than 100,000 genetic testing products and 300 personalized medicines now on the market, we know we can do better than this to help turn the tide against many of humanity's most dreadful biological foes, including cancers, rare genetic diseases, chronic conditions, and infectious diseases.
In this context, the Coalition’s three-part Strategic Plan — with overlapping emphases on education, advocacy, and evidence development — explains what PMC aspires to do in 2023 to increase investment in personalized medicine and help close the gap between what is possible and what is practiced in modern medicine.
» A Strategic Plan for Advancing Personalized Medicine in 2023